# US 12,005,088 B2 · Method of synergetic minimization of negative impact caused by flights on human health

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,005,088 B2
- Document ID: US12005088B2
- Status: Granted
- Kind: B2
- Application number: 18/129,335
- Filed: 2023-03-31
- Published: 2023-07-27
- Granted: 2024-06-11
- Earliest claimed: 2020-01-17
- Applicants: Arman Zhenisovich Lurye
- Inventors: Arman Zhenisovich Lurye
- Web page: https://patentgrep.com/patent/US12005088B2

## CPC

- A61K 35/745: Bifidobacteria
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61K 31/695: Silicon compounds
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 31/727: Heparin; Heparan
- A61K 33/08: Oxides; Hydroxides
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 33/30: Zinc; Compounds thereof
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 2035/115: {Probiotics}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention is referred to the field of medicine, namely preventative treatment, and may be used as a means of synergetic minimization of negative impact of flights on human health (brain, stomach, lungs, blood vessels, heart etc.) with application of known substances and medicines with newly discovered pharmacological properties in new conditions. The ultimate technical solution of this invention would be synergetic minimization of negative impact of flying on human health without foot swelling, belching, jet-lag, tiredness and fatigue etc. The claimed technical result is achieved by the method of synergetic minimization of negative impact of air flights on human health, including consumption of substances that improve osmotic concentration of blood plasma, in the form of oral rehydration solution, split into two intakes as a minimum, first intake in the amount of at least 0.3 liters up to 1 liter before boarding and further during the flight from half an hour to 2 hours at least 0.3 liters to 1 liter and on as-needed basis.

## Claims

### Claim 1

A kit for reducing the negative impact of air travel on a human subject by administering blood plasma osmolarity increasing preparations to the human subject, the kit comprising: at least two doses of an aqueous solution for oral rehydration solution containing sodium chloride, potassium chloride, sodium citrate, glucose, and an anticoagulant, wherein the anticoagulant is selected from the group consisting of acetylsalicylic acid, effervescent acetylsalicylic acid, warfarin, heparin and 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide, the first dose calculated for an amount of not less than 0.3 liters to 1 liter and a second dose calculated for the amount of not less than 0.3 liters to 1 liter.

### Claim 2 (depends on 1)

The kit of claim 1, wherein the anticoagulant is effervescent acetylsalicyclic acid.

### Claim 3 (depends on 1)

The kit of claim 1, wherein the anticoagulant is acetylsalicyclic acid.

### Claim 4 (depends on 1)

The kit of claim 1, wherein the anticoagulant is warfarin.

### Claim 5 (depends on 1)

The kit of claim 1, wherein the anticoagulant is heparin.

### Claim 6 (depends on 1)

The kit of claim 1, wherein the oral rehydration solution is one dose or one sachet of 18.9 g of powder containing 3.5 g sodium chloride, 2.5 g potassium chloride, 2.9 g sodium citrate, and 10 g glucose in the following ratio of components: 18.5% sodium chloride, 13.2% potassium chloride, 15.3% sodium citrate, and 52.9% glucose when dissolved in 1 liter of boiled water.

### Claim 7 (depends on 1)

The kit of claim 1, wherein the kit is used to treat in a subject in need thereof small intestine bacterial overgrowth syndrome (SIBOS) by additionally administering a therapeutically effective amount of (i) one or more probiotics or (ii) simethicone or simethicone and N-ethyl-3-phenyl-N-(3-phenylpropyl)propan-1-amine citrate or simethicone and dimethicone or (iii) a prokinetic medication.

### Claim 8 (depends on 1)

The kit of claim 1, wherein the prokinetic medication is 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]-1H-benzimidazol-2-one.

### Claim 9 (depends on 1)

The kit of claim 1, wherein the anticoagulant is 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide.

### Claim 10 (depends on 1)

The kit of claim 1, wherein the kit is used to treat dehydration and restore blood plasma osmolarity due to airline travel in a subject in need thereof.

### Claim 11 (depends on 10)

The kit of claim 10, wherein the first dose is administered to the subject before boarding an airplane, and the second dose administered to the subject in the airplane in the time interval of after half an hour and up to 2 hours after boarding the airplane.

### Claim 12 (depends on 10)

The kit of claim 10, wherein the first dose is administered 20-30 minutes before boarding an airplane.